Novartis Pipeline
Benefiting from our continued focus on innovation, Novartis has one of the industry’s most competitive pipelines. Many of these projects, which include new molecular entities as well as additional indications and different formulations for marketed products, are for medicines that could significantly advance treatment standards for patients worldwide. This table provides an overview of selected projects in development. Please note: the Novartis Pipeline data is updated quarterly.
Download the Novartis pipeline as of December 31, 2022 (PDF 0.1 MB)
- LNP023iptacopanLupus NephritisCardiovascular Phase 2 CFB inhibitor (Factor B inhibitor)
- LNP023iptacopaniAMDOphthalmology Phase 2 CFB inhibitor (Factor B inhibitor)
- LNP023iptacopanAtypical Hemolytic Uremic Syndrome (aHUS)Hematology Phase 3 >=2026 CFB inhibitor (Factor B inhibitor)
- LNP023iptacopanParoxysmal nocturnal haemoglobinuria (PNH)Hematology Phase 3 2023 CFB inhibitor (Factor B inhibitor)Lead Indication
- LNP023iptacopanImmune thrombocytopeniaHematology Phase 2 CFB inhibitor (Factor B inhibitor)
- LOU064remibrutinibChronic spontaneous urticaria (CSU)Immunology Phase 3 2024 BTK inhibitorLead Indication
- LOU064remibrutinibHidradenitis suppurativaImmunology Phase 2 BTK inhibitor
- LOU064remibrutinibFood allergyImmunology Phase 2 BTK inhibitor
- LOU064remibrutinibSjorgen’s Syndrome (SjS)Immunology Phase 2 >=2026 BTK inhibitorNew Indication
- LOU064remibrutinibMultiple sclerosisNeuroscience Phase 3 >=2026 BTK inhibitorNew Indication
- LRX712LRX712OsteoarthritisImmunology Phase 2Lead Indication
- LTP001LTP001Idiopathic pulmonary fibrosisRespiratory & Allergy Phase 2 SMURF1 inhibitor
- LTP001LTP001Pulmonary arterial hypertensionRespiratory & Allergy Phase 2 SMURF1 inhibitorLead Indication
- LXE408LXE408Visceral leishmaniosisGlobal Health Phase 2 >=2026 Proteasome inhibitorLead Indication
- MAS825MAS825Hidradenitis suppurativaImmunology Phase 2
- MAS825MAS825NLRC4-GOF indicationsImmunology Phase 2Lead Indication
- MBG453sabatolimabMyelodysplastic syndromeHematology Phase 3 2024 TIM3 Antagonist (Anti-human TIM-3 monoclonal antibody)Lead Indication
- MBG453sabatolimabLow risk myelodysplastic syndromeHematology Phase 1 TIM3 Antagonist (Anti-human TIM-3 monoclonal antibody)Supplementary Indication
- MBG453sabatolimabAcute myeloid leukaemia, maintenanceHematology Phase 2 TIM3 Antagonist (Anti-human TIM-3 monoclonal antibody)
- MBG453sabatolimabUnfit Acute myeloid leukemia (Unfit AML)Hematology Phase 2 >=2026 TIM3 Antagonist (Anti-human TIM-3 monoclonal antibody)New Indication
Pagination
- ‹‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- ›› Next page
Legend
Combination abbreviations:
fulv fulvestrant
tmx tamoxifen
gsn goserelin
NSAI Non-steroidal aromatase inhibitor
Taf Tafinlar® (dabrafenib)
Mek Mekinist® (trametinib)
a EU filing, approved in US.
b US filing, approved in EU.
c US filing, submitted in EU.
d US pending submission, approved in EU
e EU filing, submitted in US.
Disclaimer
This information was factually accurate on the date it was published. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information on this page as current or accurate after its publication date. For the latest information on the Novartis' pipeline, readers should visit the News and Investors sections of our website. This information constitutes forward-looking statements relating to Novartis AG's business, including express or implied discussions regarding potential new products, potential new indications for existing products, or regarding potential future revenues from any such products. Such forward-looking statements reflect the current views of Novartis AG regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any new products will be approved for sale in any market, or that any new indications will be approved for existing products in any market, or that such products will achieve any particular revenue levels.
In particular, management's expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays or government regulation generally; the Novartis Group's ability to obtain or maintain patent or other proprietary intellectual property protection, including the uncertainties involved in the US litigation process; competition in general; government, industry, and general public pricing and other political pressures; and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.